Published in N Engl J Med on May 18, 1978
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol (2011) 10.82
Direct demonstration that receptor crosslinking or aggregation is important in insulin action. Proc Natl Acad Sci U S A (1978) 3.15
Myasthenia gravis: past, present, and future. J Clin Invest (2006) 3.06
Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor degradation. Proc Natl Acad Sci U S A (1981) 2.18
Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci (2004) 1.78
Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 1.73
Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain (2014) 1.67
Crosslinkage and visualization of acetylcholine receptors on myotubes with biotinylated alpha-bungarotoxin and fluorescent avidin. Proc Natl Acad Sci U S A (1980) 1.50
Pathogenesis and treatment of myasthenia gravis. Br Med J (Clin Res Ed) (1981) 1.41
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest (2002) 1.31
Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology (2007) 1.16
Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci (2010) 1.13
Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol (2015) 1.13
Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process. Proc Natl Acad Sci U S A (1978) 1.10
Nicotinic acetylcholine receptor is internalized via a Rac-dependent, dynamin-independent endocytic pathway. J Cell Biol (2008) 1.06
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A (2013) 1.02
Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol (2009) 1.01
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody. J Physiol (2013) 1.00
Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry (1980) 0.97
Autoantibodies to agrin in myasthenia gravis patients. PLoS One (2014) 0.97
Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors. Proc Natl Acad Sci U S A (1980) 0.96
Divalency of the monoclonal antibody 5-1-6 is required for induction of proteinuria in rats. Clin Exp Immunol (1993) 0.93
Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci (2008) 0.92
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. Genes Immun (2009) 0.88
Adrenergic and cholinergic receptors in human nasal mucosa in cases of nasal allergy. Arch Otorhinolaryngol (1983) 0.88
Acetylcholine receptor: effects of proteolysis on receptor metabolism. J Cell Biol (1982) 0.88
Organization of acetylcholine receptor clusters in cultured rat myotubes is calcium dependent. J Cell Biol (1984) 0.87
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics (2016) 0.87
Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol (2008) 0.86
Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease. Cell Stem Cell (2015) 0.84
Autoimmune synaptopathies. Nat Rev Neurosci (2016) 0.82
Passively transferred myasthenia gravis: protection of mouse endplates by Fab fragments from human myasthenic IgG. J Neurol Neurosurg Psychiatry (1980) 0.82
Paraneoplastic syndromes. West J Med (1980) 0.82
Recombinant expression of the AChR-alpha1 subunit for the detection of conformation-dependent epitopes in Myasthenia Gravis. Neuromuscul Disord (2010) 0.82
Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation. J Neurol Neurosurg Psychiatry (1983) 0.81
Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PLoS One (2015) 0.80
Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol (1984) 0.80
Analysis of the insulin receptor by anti-receptor antibodies and flow cytometry. Proc Natl Acad Sci U S A (1984) 0.80
Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. J Anesth (2005) 0.79
Experimental autoimmune myasthenia gravis. J Neurol Neurosurg Psychiatry (1980) 0.78
Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. PLoS One (2012) 0.78
Myasthenia gravis--current concepts. West J Med (1985) 0.78
Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev (2017) 0.78
Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry (1994) 0.77
Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76
Biochemical pharmacology of paradoxical sleep. Br J Clin Pharmacol (1983) 0.76
Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75
Presynaptic membrane receptor in human brain. Indian J Clin Biochem (2012) 0.75
Inhibition of methyltransferase reduces the turnover of acetylcholine receptors. Proc Natl Acad Sci U S A (1988) 0.75
Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications. Elife (2017) 0.75
Decrease in the carbamylcholine-induced chemotaxis of monocytes in myasthenia gravis. Eur Arch Psychiatry Clin Neurosci (1991) 0.75
Tissue-specific antibodies in myasthenia gravis. J Clin Pathol Suppl (R Coll Pathol) (1979) 0.75
Extracellular synaptic factors induce clustering of acetylcholine receptors stably expressed in fibroblasts. J Cell Biol (1991) 0.75
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A (1980) 3.77
Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci U S A (1984) 2.98
Silver-Foil Psychrometer for Measuring Leaf Water Potential in situ. Science (1972) 2.87
Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science (1973) 2.86
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66
Multifocal motor neuropathy: response to human immune globulin. Ann Neurol (1993) 2.32
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Botulinum toxin: mechanism of presynaptic blockade. Science (1976) 2.19
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 2.12
"Myopathic" changes in chronically denervated muscle. Arch Neurol (1967) 2.01
Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science (1977) 1.91
Trophic regulation of acetylcholine sensitivity of muscle: effect of electrical stimulation. Science (1972) 1.77
Myasthenia gravis (first of two parts). N Engl J Med (1978) 1.74
Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med (1974) 1.71
Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1983) 1.68
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
Multiple genes encode the major surface glycoprotein of Pneumocystis carinii. J Biol Chem (1993) 1.59
Monitoring of transmitter metabolites by voltammetry in cerebrospinal fluid following neural pathway stimulation. Nature (1976) 1.52
The role of movement in the development of joints and related structures: the head and neck in the chick embryo. J Embryol Exp Morphol (1969) 1.48
Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med (1982) 1.45
Probing brain chemistry with electroanalytical techniques. Anal Chem (1976) 1.44
Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol (1995) 1.38
Caring for others: consider the emotional issues. Br J Gen Pract (1997) 1.38
Thymic muscle cells bear acetylcholine receptors: possible relation to myasthenia gravis. Science (1977) 1.36
Nafion-coated electrodes with high selectivity for CNS electrochemistry. Brain Res (1984) 1.34
Voltammetry in brain tissue--a new neurophysiological measurement. Brain Res (1973) 1.28
A new stain for quantitative measurement of sprouting at neuromuscular junctions. Muscle Nerve (1979) 1.26
Effect of muscle disuse on acetylcholine receptors. Nature (1976) 1.25
Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg (1997) 1.24
Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science (1978) 1.22
Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region. Infect Immun (1998) 1.19
New high performance liquid chromatographic analysis of brain catecholamines. Life Sci (1974) 1.19
Effects of aging on nerve sprouting and regeneration. Exp Neurol (1980) 1.17
Deduced amino acid sequence of bovine retinal Go alpha: similarities to other guanine nucleotide-binding proteins. Proc Natl Acad Sci U S A (1987) 1.17
Myasthenia gravis (second of two parts). N Engl J Med (1978) 1.16
Binding affinities of anti-acetylcholine receptor autoantibodies in myasthenia gravis. J Immunol (1982) 1.16
Potential oxidative pathways of brain catecholamines. J Med Chem (1976) 1.16
Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians. Neurology (1989) 1.16
Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology (1988) 1.16
Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol (1991) 1.15
Voltammetry in brain tissue: chronic recording of stimulated dopamine and 5-hydroxytryptamine release. Life Sci (1978) 1.15
Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci (1976) 1.15
Trophic functions of the neuron. 3. Mechanisms of neurotrophic interactions. The role of acetylcholine as a neurotropic transmitter. Ann N Y Acad Sci (1974) 1.13
Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology (2001) 1.12
Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity. J Biol Chem (1999) 1.12
Motor nerve sprouting and acetylcholine receptors. Science (1978) 1.11
Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process. Proc Natl Acad Sci U S A (1978) 1.10
Identical mitochondrial DNA deletion in blood and muscle. Lancet (1989) 1.09
Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol (1994) 1.07
Investigations into the fat pads of the sole of the foot: anatomy and histology. Foot Ankle (1992) 1.05
Myeloma neuropathy. Successful treatment of two patients and review of cases. Arch Neurol (1972) 1.05
The pathogenesis of reactive axonal swellings: role of axonal transport. J Neuropathol Exp Neurol (1977) 1.05
Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol (1987) 1.05
Denervation accelerates the degradation of junctional acetylcholine receptors. Exp Neurol (1981) 1.03
A single expression site with a conserved leader sequence regulates variation of expression of the Pneumocystis carinii family of major surface glycoprotein genes. DNA Cell Biol (1996) 1.02
Characterization of the promoter for the human 85 kDa cytosolic phospholipase A2 gene. Nucleic Acids Res (1994) 1.02
Neurotrophic regulation of muscle cholinesterase: effects of botulinum toxin and denervation. J Physiol (1972) 1.01
Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line. Am J Physiol (1993) 1.01
Neurotransmission regulates stability of acetylcholine receptors at the neuromuscular junction. J Neurosci (1989) 1.00
The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry. Brain Res (1991) 0.99
Investigations into the fat pads of the sole of the foot: heel pressure studies. Foot Ankle (1992) 0.99
Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction. Brain Res (1983) 0.98
Voltammetry in brain tissue: quantitative studies of drug interactions. Brain Res (1974) 0.98
Mechanisms of acetylcholine receptor loss in myasthenia gravis. J Neurol Neurosurg Psychiatry (1980) 0.97
P11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A2. J Biol Chem (1997) 0.97
In vivo voltammetry: monitoring of dopamine metabolites in CSF following release by electrical stimulation. Brain Res (1978) 0.97
Effect of botulinum toxin on trophic regulation of acetylcholine receptors. Nature (1977) 0.96
Cholinergic transmission regulates extrajunctional acetylcholine receptors. Exp Neurol (1980) 0.96
Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates. Muscle Nerve (1985) 0.96
Fast axonal transport in motor nerve regeneration. J Neurobiol (1976) 0.96
Electrocoating carbon fiber microelectrodes with Nafion improves selectivity for electroactive neurotransmitters. J Neurosci Methods (1987) 0.96
Impaired axonal regeneration in acrylamide intoxication. J Neurobiol (1977) 0.96
Blockade of acetylcholine receptors: a model of myasthenia gravis. Science (1975) 0.95
Neurotrophic regulation of two properties of skeletal muscle by impulse-dependent and spontaneous acetylcholine transmission. J Neurosci (1982) 0.95
Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest (1989) 0.95
Lateralization of norepinephrine in human thalamus. Science (1978) 0.94
Diffusion coefficients of neurotransmitters and their metabolites in brain extracellular fluid space. Neuroscience (1985) 0.94
Incorporation of axonally transported glycoproteins into axolemma during nerve regeneration. J Cell Biol (1981) 0.94
Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunol Immunopathol (1985) 0.94
Oral tolerance in myasthenia gravis. Ann N Y Acad Sci (1996) 0.92
Myasthenia gravis as a receptor disorder. Ann N Y Acad Sci (1976) 0.92
The biology of myasthenia gravis. Annu Rev Neurosci (1981) 0.92
In vivo dynamics of norepinephrine release-reuptake in multiple terminal field regions of rat brain. J Neurochem (1994) 0.92
Myasthenic patients' IgG causes redistribution of acetylcholine receptors: freeze-fracture studies. J Neurosci (1983) 0.91
Isaacs syndrome with laryngeal involvement: an unusual presentation of myokymia. Neurology (1979) 0.91
Electrochemical studies of the oxidation pathways of catecholamines. J Am Chem Soc (1967) 0.91
Calcium transport in isolated sarcoplasmic reticulum during muscle maturation. Nature (1968) 0.91
In vitro and in vivo depolarization coupled efflux of ascorbic acid in rat brain preparations. Brain Res Bull (1981) 0.91
Homeostatic control of ascorbate concentration in CNS extracellular fluid. Brain Res (1982) 0.91
Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol (1983) 0.90
Increase in translatable mRNA for mitochondrial pyruvate carboxylase during differentiation of 3T3 preadipocytes. Biochem Biophys Res Commun (1981) 0.90
Liquid chromatographic monitoring of CSF metabolites. Brain Res (1977) 0.89
An enhanced immunocytochemical method for staining bone marrow trephine sections. J Clin Pathol (1997) 0.89